Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
NEW YORK, Dec. 12, 2017 -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases, today announced that it will report financial results for its fiscal fourth quarter and year-ended September 30, 2017 prior to market open on Friday, December 15, 2017. The Company will also hold a live investor conference call and webcast at 8:30am Eastern Time.
| Conference Call & Webcast | |||
| Friday, December 15 @ 8:30am Eastern Time | |||
| Domestic: | 877-407-0789 | ||
| International: | 201-689-8562 | ||
| Conference ID: | 13674508 | ||
| Webcast: | http://public.viavid.com/index.php?id=127596 | ||
| Replays – Available through December 22, 2017 | |||
| Domestic: | 844-512-2921 | ||
| International: | 412-317-6671 | ||
| Conference ID: | 13674508 |
About Ohr Pharmaceutical, Inc.
Ohr Pharmaceutical, Inc. (Nasdaq:OHRP) is a clinical-stage pharmaceutical company developing novel therapies for ophthalmic diseases. The company's lead drug candidate, Squalamine lactate ophthalmic solution, 0.2% (also known as OHR-102), is currently being studied using an eye drop formulation in an ongoing clinical trial (the MAKO study) for the treatment of the wet form of age-related macular degeneration. Topline data from the MAKO study is expected in early 2018. In addition, Ohr has a sustained-release micro fabricated micro-particle ocular drug delivery platform technology. Additional information on the company may be found at www.ohrpharmaceutical.com.
Contact:
Ohr Pharmaceutical, Inc.
Investor Relations
888-388-2327
[email protected]
LifeSci Advisors, LLC
Michael Wood
646-597-6983
[email protected]
